Innovative cancer therapeutics targeting validated molecular pathways
MetCure Therapeutics LLC has developed a robust pipeline of novel small-molecule cancer therapeutics targeting distinct and validated molecular pathways. Our candidates address critical unmet medical needs across multiple cancer types, with particular focus on overcoming therapeutic resistance and targeting metastatic disease.
First-in-class small-molecule inhibitors targeting the oncogenic Skp1-Skp2 protein-protein interaction. By blocking this critical interaction, our candidates disrupt multiple downstream oncogenic signaling pathways, offering a unique mechanism for overcoming therapeutic resistance in castration-resistant prostate cancer and other malignancies.
Skp1 and Skp2 (S-phase kinase-associated protein 2) form essential components of SCF (Skp1-Cullin1-F-box) ubiquitin ligase complexes. These complexes regulate degradation of critical tumor suppressors including p27, p53, and PTEN. Aberrant Skp1-Skp2 interactions drive proliferation, invasion, and metastasis in cancer cells. Our inhibitors specifically disrupt this interaction, restoring tumor suppressor levels and inducing cell cycle arrest and apoptosis.
Approximately 33% of prostate cancer patients develop castration resistance, with 65-75% eventually developing bone metastases. Current therapies (enzalutamide, abiraterone) lose efficacy in many patients. GH501's bone-tropism and unique mechanism targeting Skp1-Skp2 interactions offers a novel approach to overcome therapeutic resistance while specifically targeting metastatic disease sites.
Novel EED-EZH2 degraders that uniquely induce degradation of PRC2 components while inhibiting PRC2 function. These candidates target aberrant histone methylation and chromatin remodeling that drives oncogenic gene silencing in multiple cancer types. Unlike traditional EZH2 inhibitors, our degrader approach provides sustained epigenetic reprogramming and overcomes compensatory resistance mechanisms.
EED (embryonic ectoderm development) and EZH2 (enhancer of zeste homolog 2) are core components of PRC2, a crucial epigenetic regulator controlling chromatin structure through H3K27 trimethylation. Dysregulated EED-EZH2 interactions lead to aberrant silencing of tumor suppressors (p16, p27, CDKN2A) while upregulating oncogenic programs. Unlike traditional EZH2 inhibitors that only block catalytic activity, our nicardipine analog series uniquely induces degradation of PRC2 components, including EED and EZH2, providing sustained epigenetic reprogramming. This dual mechanism—both inhibiting and degrading PRC2—offers more complete restoration of tumor suppressor expression and superior efficacy against chemoresistant cancers.
EZH2 mutations or overexpression occur in ~30% of diffuse large B-cell lymphomas and numerous solid tumors. PRC2 dysregulation is a key driver of chemoresistance across multiple cancer types. Our nicardipine analog series (PCT patent filed) provides a unique advantage: rather than simply inhibiting EZH2 catalytic activity, these compounds degrade PRC2 components, leading to sustained epigenetic reprogramming. This degrader mechanism overcomes compensatory resistance mechanisms and provides superior and more durable efficacy compared to traditional inhibitors. Broad applicability to chemoresistant cancers across diverse histologies.
Novel small-molecule activators of ferroptosis, an iron-dependent form of regulated cell death distinct from apoptosis and autophagy. Our ferroptosis inducers target chemotherapy-resistant and metastatic cancers that have acquired resistance to conventional cell death pathways.
Ferroptosis is characterized by iron-dependent accumulation of lipid peroxides leading to cell death. Many cancers, particularly those with acquired apoptosis resistance, remain sensitive to ferroptosis induction. Our ferroptosis inducers specifically target SLC7A11 (solute carrier family 7 member 11), which mediates system x-c cystine/glutamate antiport—a critical protective mechanism in therapy-resistant cancers. By inhibiting SLC7A11, our loratadine analogs deplete intracellular cystine, reduce glutathione synthesis, and trigger irreversible ferroptotic cell death in chemoresistant tumors.
Phase I/II trials: Safety, ferroptosis biomarker validation, and efficacy in chemoresistant cancer models
Chemoresistant cancers represent a major clinical challenge across multiple tumor types, with acquired apoptosis resistance being a key survival mechanism. These tumors remain vulnerable to ferroptosis induction. Our loratadine analog series provides a novel approach through SLC7A11 inhibition, a unique mechanism targeting system x-c cystine uptake and triggering ferroptotic cell death. The loratadine scaffold offers distinct SLC7A11 inhibitory properties, with potential for monotherapy and combination strategies with conventional chemotherapy or immunotherapy across diverse chemoresistant cancers.
A novel, patent-protected nutraceutical formulation targeting prostate cancer management and patient quality of life. ProFine® represents a dual-path strategy: immediate commercial sales as a dietary supplement with potential evolution into an FDA-regulated botanical drug.
ProFine® is a proprietary composition of three naturally-occurring flavonoid ingredients with potent anticancer activity and an excellent safety profile. Unlike traditional nutraceuticals using non-standardized whole plant extracts, ProFine® is a defined composition that can be consistently manufactured and clinically validated. The formulation demonstrates a novel mechanism of action targeting androgen receptor signaling—the central driver of prostate cancer progression.
Clinical Applications: ProFine® is positioned as a non-hormonal intervention for biochemically recurrent prostate cancer patients seeking to avoid androgen-deprivation therapy (ADT) toxicities, as an adjunct to standard-of-care therapies, and as an affordable long-term wellness intervention for the large and expanding prostate cancer survivor population.
Future Path: Development as FDA-regulated botanical drug with Phase III efficacy trials and NDA filing for "Treating Prostate Cancer and Improving Clinical Outcomes"
Advantage: Botanical drug pathway leverages history of safe human use, potentially expediting regulatory review compared to traditional synthetic drug development
Market Size: The prostate cancer nutraceutical market is estimated at $110.9M-$171.4M over 5 years with 11.5% CAGR. With 2.8 million prostate cancer survivors in the US (majority 65+ years old on Medicare), there is substantial demand for safe, affordable supportive care options.
Commercial Advantage: Unlike the 3-10 year development timelines for small-molecule drugs, ProFine® can be immediately commercialized as a dietary supplement with minimal FDA regulation. Revenue from nutraceutical sales funds botanical drug development. Strategic partnership with major nutraceutical/pharmaceutical companies provides distribution channels and capital for Phase III development. ProFine® represents a faster path to profitability while advancing toward regulated pharmaceutical status.
| Candidate | Mechanism | Indications | Stage | Timeline to IND |
|---|---|---|---|---|
| GH501 | Skp1-Skp2 Inhibitor | mCRPC (bone mets), Osteosarcoma, Pancreatic Cancer | Lead Optimization and IND-Enabling | 24-36 months |
| LG1980 Analogs | EED-EZH2 Inhibitor/Degrader | Chemoresistant Cancer | Preclinical Efficacy and ADMET | — |
| Nicardipine Analogs | EED-EZH2 Inhibitor/Degrader | Chemoresistant Cancer | Preclinical Efficacy and ADMET | — |
| Loratadine Analogs | Ferroptosis Inducer | Chemoresistant Cancer | Preclinical Efficacy and ADMET | — |
| ProFine® | HSP90/AR inhibition and ATF3 upregulation | Prostate Cancer (Wellness & Treatment Support) | Commercial Sales + Phase I/II | Immediate (Nutraceutical), 2-3 yrs (Botanical Drug) |
Four diversified programs: three small-molecule therapeutics targeting distinct molecular pathways, plus a revenue-generating nutraceutical asset. Addressing 8+ cancer indications plus prostate cancer wellness.
Active Programs
Novel Drug Targets
Cancer Indications
ProFine® Sales
Leveraging STTR and SBIR funding with academic partnerships to accelerate IND-enabling studies and reduce time to clinical development.
Seeking collaboration and licensing opportunities with pharmaceutical partners for clinical development and commercialization.
All studies conducted to GLP/GCP standards with rigorous safety pharmacology and comprehensive IND packages prepared.
Contact us to discuss partnership, licensing, or collaboration opportunities.
Get in Touch